Pharmaceutical Outsourcing
Welcome GuestUnited States
Sign In Register

  • Home
  • API
  • Manufacturing
  • Clinical Trials
  • Analytical Testing
  • Cold Chain
  • Articles
    • Facility Tours
  • News
  • Events
  • Videos
    • Clinical Trials Documentary
    • A Solid Dosage Future Documentary
  • Whitepapers/App Notes
  • Issue Archives
  • Company Focus
  • Service Directory
  • Register
  • Sign In

Logo

Using Patient Specific iPSC-Cardiomyocytes for Disease Modeling

Ulrich Broeckel, MD
Tuesday, March 31, 2015
Tweet
Transcript Embed
  • Email
  • Bookmark

Chapters

  • Introduction
  • Conflict of Interest
  • CONGRATULATIONS!
  • Generate data; Interpret data? Implement data?
  • Questions
  • Translational Precision Medicine
  • Next Steps Concept
  • Left Ventricular Hypertrophy
  • Study Population
  • iPS Derivation Status
  • CM Quality Parameters
  • Human Cardiomyocyte Model of Hypertrophy
  • HT Assay Platform
  • Protocol Development
  • First Round of Production Phenotyping: African American
  • miRNA and Cardiovascular Disease
  • miRNA Sequence Analysis
  • Knock Down: Predicted miRNAs
  • Knock Down: Expression Analysis
  • Variation Between Lines
  • Variation between iPSC-CM Lines
  • Develop Drug Screening Assay
  • Primary Screen at 5μM Hits >50% activity compared with Macitentan control
  • Develop Drug Screening Assay
  • Summary
  • Acknowledgement
 

No transcript for this webinar

More InformationRequest info
  • <<
  • <
  • >
  • >>

Videos

  • On-Demand Webinar: The ABCs and 123s of the BCS

    Tuesday, September 01, 2020

  • Live Webinar: AAV Gene Therapy; A Road Map to IND ...

    Thursday, April 23, 2020

  • Watch Live Webinar: Dodge the Particle Panic: ...

    Tuesday, April 07, 2020

  • On-Demand Webinar: Extractables and Leachables of ...

    Thursday, November 21, 2019

  • On-Demand Webinar: Formulating to Enable High ...

    Thursday, September 26, 2019
Page
  • <<
  • <
  • 1
  • 2
  • 3
  • 4
  • >
  • >>